| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Precipio, Inc. Common Stock$21.65
+0.46 (+2.17%)
Market Cap
48.61 M
EPS
-0.29
P/E Ratio
-93.23 $
Value Trade
1.42 M
SEC Financials
Q3 2025Dilution Risk
Revenue
6.77 M
Total Assets
21.15 M
Total Liabilities
7.40 M
Equity
13.75 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.31 M
Monthly Burn
20.00 K
Runway
111.3 mo
Burn Trend
SEC Filing
Nov 14, 2025
Overview
Volume
21.13 K
52 Week Range
5.09 - 29.53
% held by Insiders
12.59 %
% held by Institutions
17.36 %
Enterprise Value
49.61 M
Total Shares
1.79 M
Short %
1.69 %
Float Shares
1.64 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BCR::ABL1 assay | — | — | 2025-12-08 | The joint study with Memorial Sloan Kettering Cancer Center evaluated Precipio’s BCR::ABL1 assay using 895 patient samples, demonstrating superior performance and concordance with two leading platforms, positively impacting patient care and laboratory workflows. Read More | Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Read More | |
BCR::ABL1 assay | — | — | 2025-12-08 | The joint study with Memorial Sloan Kettering Cancer Center evaluated Precipio’s BCR::ABL1 assay using 895 patient samples, demonstrating superior performance and concordance with two leading platforms, positively impacting patient care and laboratory workflows. Read More | Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Read More | |
BCR::ABL1 assay | — | — | 2025-12-08 | The joint study with Memorial Sloan Kettering Cancer Center evaluated Precipio’s BCR::ABL1 assay using 895 patient samples, demonstrating superior performance and concordance with two leading platforms, positively impacting patient care and laboratory workflows. Read More | Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRPO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRPO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PRPO
Jul 31, 2026▲ +2.2%today
Precipio Announces Q2-2026 Shareholder Update Call
Precipio, Inc. will host its Q2-2026 shareholder update call on August 17, 2026. CEO Ilan Danieli expressed optimism about the company's growth and customer acquisition. The call will feature a moderated Q&A session, allowing investors to engage directly with management. A replay will be available post-call on the company's website.
Read more →-PRPO
Jun 12, 2026Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio, Inc. is urging shareholders to vote their shares before the June 14 deadline to ensure a quorum for the Annual Shareholders Meeting scheduled for June 15, 2026. Currently, only 42% of shares have been voted, and a minimum of 50% is required. Management seeks to avoid the costs associated with adjourning the meeting due to insufficient votes.
Read more →-PRPO
Jun 11, 2026Precipio to Present at the Planet MicroCap Las Vegas
Precipio, Inc. will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation, focusing on building shareholder awareness. The event aligns with Precipio's strategy to enhance its shareholder base without seeking additional capital.
Read more →-PRPO
May 14, 2026Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported its Q1 2026 financial results, showing stable revenue of $6.71 million, slightly up from the previous year. The company anticipates growth in the second half of the year due to an expanding product pipeline. However, challenges included a temporary decline in product revenue and a significant decrease in adjusted EBITDA. The CEO emphasized the importance of assessing non-commercial fluctuations in the business.
Read more →-PRPO
May 13, 2026Management team’s 2025 market-based Options have vested
Precipio, Inc. announced that its management team's 2025 stock options vested after the company's share price rose over 400% from $6 to $30.30. This market-based vesting structure aligns management incentives with shareholder interests, as options only vest with significant price increases. A similar structure is planned for the 2026 stock option grant.
Read more →-PRPO
May 6, 2026▼ -6.8%on this news
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. will host its Q1-2026 shareholder update call on May 18, 2026, at 5:00 PM ET. This call will feature a moderated live Q&A session for the first time, allowing shareholders to engage directly with management. The company aims to provide insights into its performance and growth strategies.
Read more →-PRPO
May 6, 2026▼ -7.4%on this newsshared move
Precipio Announces Q1-2026 Shareholder Update Call Conference Call will be held on May 18th, 2026, at 5:00 PM EST NEW HAVEN, CT, (May 6 th , 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , wi
Precipio, Inc. announced it will hold its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM EST. This call will include updates on the company’s core businesses and feature a live moderated Q&A session for shareholders. The introduction of the Q&A session highlights Precipio's dedication to transparency and engagement with its investors. Participants can submit questions in advance and gain insights into the company's performance and strategic direction.
Read more →-PRPO
Mar 13, 2026▼ -6.7%on this news
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Precipio, Inc. will hold its Q4 and year-end 2025 corporate update call on April 2, 2026. The call aims to provide updates on the company's core businesses and will allow shareholders to submit questions in advance. Precipio focuses on enhancing cancer diagnostics to reduce misdiagnoses and improve patient outcomes.
Read more →-PRPO
Mar 10, 2026Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
Precipio, Inc. has published a study in collaboration with Memorial Sloan-Kettering Cancer Center, showcasing its Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). This assay uniquely quantifies all four clinically relevant BCR::ABL1 isoforms, enhancing disease monitoring and treatment decisions. The study analyzed 895 samples, demonstrating significant advantages over existing assays.
Read more →-PRPO
Feb 25, 2026Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Precipio, Inc. reported preliminary unaudited revenues of $24.0 million for 2025, marking a 30% increase from the previous year. The company has achieved EBITDA and cash-flow positivity, allowing for investments in long-term growth. CEO Ilan Danieli highlighted the positive performance and tripling of shareholder value, with further details expected in an upcoming shareholder call.
Read more →-PRPO
Jan 15, 2026Precipio Takes Major Steps Toward a Clean Balance Sheet
Precipio, Inc. has made significant progress in improving its financial standing by repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants. The company now maintains a debt-free balance sheet, with only a minor loan remaining. CEO Ilan Danieli emphasized the focus on growth and shareholder value.
Read more →-PRPO
Dec 8, 2025Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Precipio, Inc. will present findings from a joint study with Memorial Sloan Kettering at the 2025 ASH Meeting. The study, involving 895 patient samples, highlights the superior performance of Precipio's BCR::ABL1 assay and its positive effects on patient care and laboratory workflows. The poster presentation is scheduled for December 8th in Orlando, Florida.
Read more →-PRPO
Dec 4, 2025Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
Precipio, Inc. reported a limited unauthorized access incident to a data folder in its cloud storage. The breach did not affect operations or patient care, and the company has engaged cybersecurity experts for investigation. Current findings suggest the incident was contained, with no sensitive data compromised. Precipio expects no material impact on its operations or finances.
Read more →-PRPO
Nov 14, 2025Precipio Announces its Q3-2025 Financial Results
Precipio, Inc. reported strong financial results for Q3-2025, with revenues of $6.8 million, reflecting a 30% increase year-over-year. The company achieved positive Adjusted EBITDA of $469,000, a significant improvement from the previous quarter. Cash flow from operations also turned positive, generating $285,000. The Pathology Services Division showed notable growth, indicating a robust customer pipeline.
Read more →-PRPO
Nov 6, 2025Precipio Announces Q3-2025 Shareholder Update Call Conference Call to be held on November 17 th , 2025 at 5:00 PM EST NEW HAVEN, CT, (November 4 th , 2025) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: P
Precipio, Inc. (NASDAQ: PRPO) has announced a Q3-2025 shareholder update call scheduled for November 17, 2025, at 5:00 PM EST. The call will provide updates on the company's core businesses and address questions submitted in advance by investors. Precipio is committed to developing innovative cancer diagnostic solutions that aim to improve accuracy and patient outcomes. A replay of the call will be accessible via the company's Investor page 24 hours later.
Read more →-PRPO
Nov 4, 2025Precipio Announces Q3-2025 Shareholder Update Call
Precipio, Inc. will hold its Q3-2025 corporate update call on November 17, 2025. The call aims to provide insights into the company's current core businesses and will be accessible via phone. Investors can submit questions in advance, and a replay will be available post-call.
Read more →-PRPO
Sep 2, 2025Precipio Terminates Its ATM
Precipio, Inc. has terminated its At-The-Market (ATM) instrument with Alliance Global Partners, signaling a stronger financial position. CEO Ilan Danieli stated that the company no longer needs this tool for capital raises due to improved cash flow and increased cash reserves. This decision reflects Precipio's commitment to responsible capital management and shareholder value.
Read more →-PRPO
Aug 18, 2025Diagnostics Biotech Company NASDAQ: PRPO Founded in 2011 HQ: New Haven, CT DISCLAIM ER T HIS PRESENT AT ION HAS BEE N PREPARE D B Y P RE CIPIO IN C. (T HE “C O MPAN Y”) AND IS GENERA L BA CKGROUND IN FOR MA
Precipio, a diagnostics biotech company, offers a proprietary diagnostics platform that aims to revolutionize blood cancer diagnostics with rapid and cost-effective solutions. The company is projecting significant growth potential as it expands its market footprint into molecular diagnostics valued at over $40 billion. Precipio's innovative testing solutions address critical industry challenges, such as labor shortages and streamline patient care processes. The company maintains a cash flow positive business model and optimizes product delivery through established national distribution partnerships.
Read more →-PRPO
Aug 13, 2025Precipio Announces its Q2-2025 Financial Results
Precipio, Inc. reported a strong Q2-2025 financial performance with revenues reaching $5.7 million, a 27% increase year-over-year. The company anticipates becoming cash flow positive by the end of the year, supported by growth in both its Products and Pathology Services divisions. Adjusted EBITDA showed significant improvement, reflecting effective cost management.
Read more →-PRPO
Jul 31, 2025Precipio Announces Q2-2025 Shareholder Update Call Conference Call to be held on August 14 th , 2025 at 5:00 PM EST NEW HAVEN, CT, (July 31 st , 2025) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO )
Precipio, Inc. (NASDAQ: PRPO) has announced a Q2-2025 shareholder update call scheduled for August 14, 2025, at 5:00 PM EST. The call will cover updates on the company's core businesses and allow for advance questions from interested parties. Precipio is focused on cancer diagnostics, aiming to improve accuracy in diagnosing cancer to enhance patient outcomes and reduce healthcare costs. Information about the call will be available on the company's website afterwards.
Read more →-PRPO
Jul 11, 2025Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Precipio, Inc. has amended its agreement with its largest warrant holder, allowing for a combination of cash and cashless exercises of warrants. This change will reduce the number of shares added to outstanding shares and secure approximately $1.2 million in cash inflow. The company plans to discuss this transaction further during its upcoming quarterly shareholder call.
Read more →-PRPO
May 15, 2025Precipio Announces its Q1-2025 Financial Results Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, CT, (May 14th, 2025) - Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) , filed its 1
Precipio, Inc. reported its Q1-2025 financial results and highlighted significant year-over-year revenue growth. The company's Pathology Services division experienced a 54% increase in revenue, driven by a higher test volume. Additionally, Precipio is hopeful for continuous growth, with expectations of returning to positive operating cash flow in the upcoming quarters. The management expressed confidence in their operational efficiency and the potential for scalable growth throughout 2025.
Read more →-PRPO
May 14, 2025Precipio Announces its Q1-2025 Financial Results
Precipio, Inc. reported a strong Q1-2025 with a 43% increase in revenues year-over-year, reaching $4.9 million. The company also noted a significant improvement in Adjusted EBITDA, which was a loss of $108,000 compared to a loss of $1.4 million last year. Despite a decrease in revenues from the previous quarter, management expects a return to positive cash flow by mid-2025, supported by growth in both its Product and Pathology Services divisions.
Read more →-PRPO
May 6, 2025Precipio Announces Q1-2025 Shareholder Update Call Conference Call to be held on May 15 th , 2025 at 5:00 PM EST NEW HAVEN, CT, (May 1 st , 2025) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will
Precipio, Inc. (NASDAQ: PRPO) has announced a corporate update call scheduled for May 15th, 2025, at 5:00 PM ET. This call will cover updates on the company's core businesses. Participants can pre-register to receive a direct dial-in and are encouraged to submit questions in advance. Precipio focuses on enhancing accuracy in cancer diagnostics, which may reduce healthcare costs and improve patient outcomes.
Read more →-PRPO
May 1, 2025▲ +6.7%on this news· ran to +23% by day 1shared move
Precipio Announces Q1-2025 Shareholder Update Call
Precipio, Inc. will host its Q1-2025 corporate update call on May 15, 2025, at 5:00 PM ET. The call will provide updates on the company's core businesses and allow for shareholder engagement through pre-submitted questions. Precipio aims to improve cancer diagnostics and reduce misdiagnoses.
Read more →-PRPO
Mar 17, 2025▲ +11.7%on this news
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
Precipio, Inc. will hold its Q4 and year-end 2024 corporate update call on March 31, 2025. The call aims to provide shareholders with updates on the company's core businesses and will allow participants to submit questions in advance. A replay of the call will be available shortly after it concludes.
Read more →-PRPO
Mar 17, 2025▲ +9.2%on this newsshared move
Precipio Announces Q4 and year-end 2024 Shareholder Update Call Conference Call to be held on March 31 st , 2025 at 5:00 PM EST NEW HAVEN, CT, (March 17th, 2025) - Specialty cancer diagnostics company Precipio, Inc. (NAS
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, has announced a corporate update call scheduled for March 31, 2025. This call will cover updates regarding the company's core business operations. The call emphasizes Precipio's commitment to transparency with its shareholders and the importance of addressing cancer misdiagnoses through their diagnostic solutions.
Read more →-PRPO
Feb 25, 2025▼ -12.7%on this news· ran to -25% by day 1
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Precipio, Inc. reported significant financial achievements for Q4-2024, including a positive Adjusted EBITDA of $0.4 million and a cash flow increase of $0.3 million. These results indicate the company's potential for financial independence and sustained growth. However, management cautions that future performance may vary, particularly in the first quarter due to insurance deductible impacts.
Read more →-PRPO
Jan 16, 2025Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
Precipio, Inc. announced a new performance-based vesting structure for senior management stock options, which will vest only if the stock price reaches five times the exercise price. This decision reflects the management's confidence in the company's growth potential. The entire senior management team opted for this structure, indicating their belief in achieving significant share price increases.
Read more →-PRPO
Jan 16, 2025Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs These options vest when PRPO stock price is 5x the exercise price NEW HAVEN, CT, (
Precipio, Inc. (NASDAQ: PRPO) has granted its senior management performance-based stock options that will vest only if the company's stock price reaches five times the exercise price, set at $6.06. This decision, supported unanimously by management, is intended to incentivize efforts to maximize company performance and align interests with those of shareholders. The new structure replaces the traditional time-vested Employee Stock Ownership Plans (ESOPs), reflecting management's confidence in their ability to significantly increase the stock value within the next few years. Other employees will continue to receive time-based options.
Read more →-PRPO
Nov 7, 2024Precipio Announces Q3-2024 Shareholder Update Call Conference Call to be held on
Precipio, Inc. (NASDAQ: PRPO) announced it will hold a corporate update call for Q3-2024 on November 18, 2024, at 5:00 PM ET. This call will discuss the financial highlights and business analysis following the filing of their Q3-2024 10-Q. Investors are invited to participate by calling in or pre-registering online, and they can submit questions in advance to be addressed during the call. A replay will be available on Precipio's website shortly after the call concludes.
Read more →-PRPO
Nov 6, 2024Precipio Announces Q3-2024 Shareholder Update Call
Precipio, Inc. will hold its Q3-2024 corporate update call on November 18, 2024, at 5:00 PM ET. The call will discuss the company's financial performance and core business analysis following the release of its Q3-2024 10-Q report. Participants can submit questions in advance and access a replay of the call afterward.
Read more →-PRPO
Oct 8, 2024Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
Precipio, Inc. has launched an updated Bloodhound MPN panel capable of distinguishing between CALR type 1 and type 2 mutations. This advancement is significant for treatment decisions in myeloproliferative neoplasms (MPN) and aligns with the latest NCCN guidelines. The new assay aims to enhance patient care by providing critical mutation data that influences prognosis and therapy selection.
Read more →-PRPO
Sep 6, 2024Precipio Announces Employee Stock Option Plan Repricing
Precipio, Inc. has announced the repricing of employee stock options to enhance retention in a competitive market. This strategic move aims to align employee incentives with shareholder value, addressing the issue of underwater options. Management believes this change will benefit both employees and shareholders, despite potential concerns from long-term investors.
Read more →-PRPO
Aug 15, 2024▲ +6.3%on this news· ran to +25% by day 3
Precipio Announces Q2-2024 Shareholder Update Call
Precipio, Inc. will hold its Q2-2024 corporate update call on August 19, 2024, at 5:00 PM ET. The call aims to provide insights into the company's core businesses and allows shareholders to submit questions beforehand. A replay will be available approximately 24 hours after the call.
Read more →-PRPO
Aug 15, 2024▲ +6%on this news· ran to +24% by day 3shared move
Precipio Announces Q2-2024 Shareholder Update Call Conference Call to be held on
Precipio, Inc. (NASDAQ: PRPO) will hold its Q2-2024 corporate update call on August 19, 2024, at 5:00 PM EST. The call aims to provide updates on the company's core business activities and listeners can submit questions in advance. The company emphasizes its commitment to improving diagnostic accuracy in cancer care through collaboration with leading academic institutions. A replay of the call will be available on the company's website shortly after the event.
Read more →-PRPO
Jul 25, 2024▲ +8%on this news
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
Precipio, Inc. reported a cash generation of $0.3 million for Q2-2024, indicating a positive trend in its financial health. With cash reserves of approximately $1.3 million, the company is optimistic about achieving breakeven by the end of the year. The CEO emphasized the importance of financial independence and the avoidance of dilutive transactions.
Read more →-PRPO
Jul 17, 2024▲ +23.9%on this news
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Precipio, Inc. reported a 30% increase in unaudited revenues for Q2-2024, reaching $4.4 million. The Pathology Division has achieved breakeven and is expected to continue growing, with projections of over $1.5 million monthly by year-end. The Products Division is onboarding key accounts that will further enhance revenue. CEO Ilan Danieli expressed optimism about the company's trajectory towards profitability.
Read more →-PRPO
Jun 13, 2024Precipio, Inc. Announces Adjournment of Annual Meeting of Stockholders
Precipio, Inc. has announced the adjournment of its 2024 Annual Meeting of Shareholders due to insufficient quorum. The meeting will reconvene on June 21, 2024, at 9 a.m. Eastern Time. Shareholders are encouraged to ensure their votes are submitted to avoid further delays in decision-making.
Read more →-PRPO
Jun 12, 2024Precipio Provides Status Update on Current Business Matters
Precipio, Inc. reports a positive update on its business operations, indicating a recovery in its pathology division revenue and new customer acquisitions. The company has addressed prior operational challenges and anticipates a return to breakeven in Q3-2024. Additionally, the recent FDA ruling on Laboratory Developed Tests (LDTs) will require compliance but is expected to position Precipio competitively. The upcoming shareholders meeting is scheduled for June 13, 2024.
Read more →-PRPO
May 6, 2024Precipio Secures a short-term $500K Credit Facility
Precipio, Inc. has secured a $500K short-term credit facility to address cash flow delays caused by a recent cybersecurity attack on Change Healthcare. The loan will help manage temporary cash collection issues while ensuring operational liquidity. CEO Ilan Danieli reassured stakeholders that this situation is not expected to materially impact the business.
Read more →-PRPO
May 6, 2024Precipio Secures a short-term $500K Credit Facility Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack NEW HAVEN, CT, (May 6 th , 2024) - S
Precipio, Inc. has obtained a $500K short-term credit facility to mitigate cash flow delays stemming from a cybersecurity attack on Change Healthcare. The attack, which occurred in early 2024, disrupted cash collection processes that many healthcare companies, including Precipio, rely on for their operations. However, Precipio stated that its own IT infrastructure remains unaffected and that the cash flow issue is expected to be temporary. The company plans to utilize the funds to ensure adequate liquidity while continuing its path toward profitability.
Read more →-PRPO
Mar 26, 2024Precipio Announces Year end 2023 Shareholder Update Call Conference Call to be held on April 1 st , 2024 at 5:00 PM EST NEW HAVEN, CT, (March 25 th , 2024) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: P
Precipio, Inc. (NASDAQ: PRPO) is set to hold its year-end 2023 shareholder update call on April 1, 2024, at 5:00 PM EST. The call aims to provide updates on the company's core businesses, which focus on cancer diagnostics to reduce misdiagnoses. Participants can submit questions in advance and access the call via a provided link. Additionally, a replay will be available on the company's investor webpage shortly after the call concludes.
Read more →-PRPO
Mar 25, 2024▼ -5.5%on this newsshared move
Precipio Announces Year end 2023 Shareholder Update Call
Precipio, Inc. will hold its year-end 2023 corporate update call on April 1, 2024, at 5:00 PM ET. The call aims to provide updates on the company's core business activities. Participants can join via phone or pre-register for a direct dial-in. Questions can be submitted in advance for management to address during the call.
Read more →-PRPO
Feb 13, 2024Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Precipio, Inc. reported a 60% increase in unaudited revenues for FY-2023, rising from $9.4M in 2022 to $15.2M. The growth was driven by significant increases in both the pathology services and products divisions. The company's cost-cutting measures have also led to a substantial reduction in cash burn, positioning it to achieve profitability.
Read more →-PRPO
Feb 6, 2024▲ +8.2%on this news
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
Precipio, Inc. has signed a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. This partnership aims to enhance Precipio's distribution capabilities primarily within acute healthcare systems and laboratories. CEO Ilan Danieli expressed optimism about the collaboration, highlighting its potential to drive growth in 2024.
Read more →-PRPO
Jan 23, 2024Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Precipio, Inc. reported a significant reduction in Cash Burn From Operations, dropping below $100K in Q4-2023. This marks a 90% decrease from the previous quarter, indicating progress towards breakeven. However, management cautions that Q1-2024 may face challenges due to seasonal revenue declines and insurance resets affecting cash flow.
Read more →-PRPO
Jan 17, 2024▲ +15.4%on this news· ran to +27% by day 1
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
Precipio, Inc. has signed a distribution agreement with a Japanese distributor for its IV-Cell cytogenetics media. The agreement follows a successful evaluation by a leading Japanese clinical laboratory, which placed the first order. This partnership aims to leverage the distributor's network to enhance Precipio's presence in the Japanese market and potentially other global markets.
Read more →-PRPO
Jan 2, 2024Precipio Announces Christina Valauri joins the Board of Directors
Precipio, Inc. has appointed Christina Valauri to its board of directors, effective January 1, 2024. Valauri, a seasoned healthcare analyst, will aid the company in navigating capital markets as it aims for growth in 2024. Douglas Fisher, MD, will step down from his director role but remain a board observer.
Read more →-PRPO
Jan 2, 2024Precipio Announces Christina Valauri joins the Board of Directors Douglas Fisher, MD will step down as Director, and remain as a board observer NEW HAVEN, CT, Globenewswire - (
Precipio, Inc. has appointed Christina Valauri to its Board of Directors, effective January 1, 2024. Valauri, a seasoned healthcare analyst, is expected to strengthen interaction with capital markets during a pivotal growth phase for the company. Douglas Fisher, MD, will step down as a director but remain a board observer, affirming his ongoing support for Precipio's strategic direction. This leadership change aims to enhance shareholder value as the company focuses on innovations in cancer diagnostics.
Read more →-PRPO
Dec 14, 2023Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
Precipio, Inc. has reflected on its performance in 2023, achieving two of its three financial targets aimed at reaching cash flow breakeven. The company reported a significant reduction in cash burn and anticipates a 50% revenue growth in 2024. However, management cautions about revenue volatility in the pathology division and sporadic growth in the products division.
Read more →-PRPO
Dec 14, 2023▲ +12.4%on this newsshared move
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024 NEW HAVEN, CT, Globenewswire - (
Precipio, Inc. (NASDAQ: PRPO) reflects on its 2023 performance and sets optimistic goals for 2024. The company met two out of three goals aimed at achieving cash flow breakeven, including surpassing $3.75M in pathology division revenues and significantly reducing cash burn. Looking forward, with an anticipated growth rate of 50%, Precipio aims for an annual run-rate of approximately $30M, which could lead to positive cash flow in the latter half of 2024. The management emphasizes their focus on core product division goals despite potential fluctuations in pathology revenues.
Read more →-PRPO
Nov 16, 2023▼ -8.3%on this news
Precipio Announces Q3-2023 Shareholder Update Call
Precipio, Inc. will hold its Q3-2023 corporate update call on November 20, 2023, at 5:00 PM ET. The call aims to update shareholders on the company's core business activities. Participants can pre-register and submit questions in advance. A replay will be available on the company's website shortly after the call.
Read more →-PRPO
Nov 16, 2023Precipio Announces Q3-2023 Shareholder Update Call Conference Call to be held on November 20 th , 2023 at 5:00 PM EST NEW HAVEN, CT, (November 16 th , 2023) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:
Precipio, Inc. has announced its Q3-2023 shareholder update call, scheduled for November 20th, 2023, at 5:00 PM EST. The call will provide updates on the company's core businesses and allow for participation from shareholders and interested parties. Precipio aims to improve diagnostic accuracy in cancer care and encourages advance questions from investors. The announcement emphasizes the company's focus on delivering quality diagnostic information through collaborations with leading academic institutions.
Read more →-PRPO
Oct 18, 2023Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
Precipio, Inc. reported a significant revenue increase of 28% in Q3-2023, reaching $4.5 million, which is more than double the revenue from Q3-2022. The growth is attributed to advancements in both pathology and product divisions, as well as cost reduction initiatives. The company aims to reach a $20 million run rate and is moving towards breakeven in operating cash flow.
Read more →-PRPO
Oct 3, 2023Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Precipio, Inc. reported a significant reduction in cash burn from operations, decreasing from $2.5 million in Q3 2022 to approximately $1 million in Q3 2023. The company expects its current cash levels to be sufficient to achieve financial independence without needing additional capital raises. Revenue growth and cost-cutting measures are driving this improvement, particularly in the Pathology division.
Read more →-PRPO
Sep 28, 2023Precipio Continues to Sign New HemeScreen™ Customers
Precipio, Inc. announced new customer orders projected to generate $1.2M in Q4 HemeScreen revenues. The company has reduced its cash flow breakeven target to $6M annualized run rate, with Q4 revenues nearing this goal. CEO Ilan Danieli expressed optimism about the product's market position and the company's ability to capture substantial market share.
Read more →-PRPO
Sep 25, 2023Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Precipio, Inc. has lowered its annual product revenue breakeven point from $8 million to $6 million due to increased pathology revenues and operational efficiencies. The company anticipates reaching cash flow breakeven sooner, driven by improved gross margins and cost reduction initiatives. CEO Ilan Danieli expressed optimism about achieving financial independence.
Read more →-PRPO
Sep 21, 2023▼ -10.4%on this newsshared move
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
Precipio, Inc. has executed a 1-for-20 reverse stock split to comply with Nasdaq's minimum bid price requirement. This move is intended to enhance the company's market perception and attract a broader investor base. Management is optimistic about future revenue growth and aims to achieve financial independence, despite potential shareholder concerns regarding the split's implications.
Read more →-PRPO
Sep 21, 2023▼ -10.4%on this newsshared move
Precipio Takes Final Step Towards Regaining Nasdaq Compliance Company announces 1-for-20 reverse stock split NEW HAVEN, CT - (
Precipio, Inc. announced a 1-for-20 reverse stock split to comply with Nasdaq's minimum bid price requirement. The reverse split aims to raise the share price and broaden the investor pool, as companies trading below certain thresholds are often dismissed by institutional investors. Despite some negative sentiment surrounding reverse stock splits, management emphasizes the company's positive trajectory, including revenue growth and an increasing customer base. The reverse split is set to take effect after market close on September 21, 2023.
Read more →-PRPO
Sep 13, 2023▲ +7.8%on this news
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
Precipio, Inc. announced that its Pathology Division surpassed its breakeven revenue target in August, achieving over $1.2 million in revenue. This milestone, reached four months ahead of schedule, positions the division to contribute positively to the company's finances. Management expresses confidence in sustaining this growth momentum into September and beyond.
Read more →-PRPO
Aug 17, 2023Precipio Announces Q2-2023 Shareholder Update Call Conference Call to be held on
Precipio, Inc. (NASDAQ: PRPO) has announced its Q2-2023 corporate update call scheduled for August 17, 2023, at 5:00 PM ET. The call will provide insights into the company's core businesses and advancements in cancer diagnostics. Investors have the opportunity to submit questions ahead of the call, which emphasizes Precipio's commitment to communication and shareholder engagement. Following the call, a replay will be available on their website.
Read more →-PRPO
Aug 10, 2023Precipio Announces Q2-2023 Shareholder Update Call
Precipio, Inc. will hold its Q2-2023 corporate update call on August 17, 2023, at 5:00 PM ET. The call aims to provide updates on the company's core businesses and allows participants to submit questions in advance. A replay will be available on the company's website following the call.
Read more →-PRPO
Aug 8, 2023Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Precipio, Inc. has launched its new Quantitative BCR-ABL 2.0 panel, which is designed to enhance the diagnosis and monitoring of Chronic Myeloid Leukemia (CML). The panel offers superior sensitivity, comprehensive clinical coverage, and simplified laboratory workflows. Initial pre-orders are already in the six-figure range, indicating strong market demand. The product aims to improve patient care and streamline laboratory operations.
Read more →-PRPO
Aug 3, 2023Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
Precipio, Inc. has reported a 26% reduction in cash burn for the first half of 2023, totaling $3.1 million. The company anticipates further decreases in cash burn due to various operational efficiency measures, including in-house testing and billing. These initiatives aim to enhance profitability and move the company closer to breakeven. CEO Ilan Danieli expressed optimism about the company's direction and commitment to delivering positive results.
Read more →-PRPO
Aug 1, 2023▲ +5.7%on this newsshared move
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Precipio, Inc. reported a 25% increase in revenues for Q2-2023, reaching $3.5M compared to $2.8M in Q1-2023. The growth is attributed to strong performance in both the products and pathology services divisions, alongside an expanding customer pipeline. CEO Ilan Danieli expressed optimism about the company's operational progress and financial goals.
Read more →-PRPO
Jun 12, 2023▼ -5.9%on this news
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement NEW HAVEN, CT, (June 8 th , 2023) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today an
Precipio, Inc. announced a $2 million funding initiative through the pricing of a registered direct offering alongside a concurrent private placement. The securities purchase agreements involve the sale of over 4 million shares and pre-funded warrants, with a nominal purchase price of $0.45. This funding is intended for working capital and general corporate purposes, with the closing expected around June 12, 2023. The announcement highlights the company's dedication to enhancing cancer diagnostic accuracy through innovative technological solutions.
Read more →-PRPO
May 17, 2023Precipio Announces Q1-2023 Shareholder Update Call Conference Call to be held on
Precipio, Inc. is set to hold its Q1-2023 corporate update call on May 17, 2023, at 5:00 PM ET. This call will cover updates on the company's core business operations. Interested parties can participate via phone or register online for direct dial-in access. Precipio emphasizes its mission to enhance diagnostic accuracy and improve patient care through collaborations with leading academic institutions.
Read more →-PRPO
Apr 27, 2023Precipio Granted 180-day Extension From NASDAQ To Regain Compliance Extension will enable the Company to execute on its growth and advance toward breakeven NEW HAVEN, CT, Globenewswire - (
Precipio, Inc. has been granted a 180-day extension from NASDAQ to comply with its minimum share price requirement of $1.00 for continued trading on the exchange. The company reports positive preliminary results for Q1-2023, indicating potential revenue growth and a path toward breakeven. Management remains optimistic about the potential for share price appreciation and overall company performance during this period. Precipio continues to aim for achieving its financial targets and enhancing diagnostic accuracy through its proprietary technologies.
Read more →-PRPO
Mar 29, 2023Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call Conference Call to be held on Monday, April 3 rd , 2023 at 5:00 PM EST NEW HAVEN, CT, Globenewswire - (March 28 th , 2023) - Specialty cancer di
Precipio, Inc. is set to host its Q4 2022 and year-end shareholder update call on April 3, 2023. This call will provide important updates regarding the company's core businesses and future plans. Participants can pre-register for the call and submit questions in advance. The company emphasizes its commitment to improving diagnostic accuracy through collaborations with leading academic institutions, which is fundamental to enhancing patient care.
Read more →-PRPO
Nov 4, 2022Precipio Announces Third Quarter Shareholder Update Call Conference Call to be held on Monday, November 14 th , 202 2 at 5:00 PM ET NEW HAVEN, CT, Globenewswire - (November 2 nd , 2022) - Specialty cancer diagnostics com
Third Quarter Shareholder Update Call Call to be held on Monday, November 14th, 2022 at 5:00 PM ET HAVEN, CT, Globenewswire - (November 2nd, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monda
Read more →-PRPO
Aug 8, 2022Precipio Announces Second Quarter Shareholder Update Call Conference Call to be held on Monday, August 15 th , 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire - (August 8 th , 2022) - Specialty cancer diagnostics compan
Announces Second Quarter Shareholder Update Call Call to be held on Monday, August 15th, 2022 at 5:00 PM EST HAVEN, CT, Globenewswire - (August 8th, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2022 shareholder update call
Read more →-PRPO
Jul 21, 2022Precipio to distribute HemeScreen through Fisher Healthcare channel Agreement Enhances Precipio's Product Reach to US Laboratories NEW HAVEN, CT - (Globe Newswire) - (July 20 th , 2022) - Specialty cancer diagnostics com
to distribute HemeScreen through Fisher Healthcare channel Agreement Enhances Precipio's Product Reach to US Laboratories (Globe Newswire) - (July 20th, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agr
Read more →-PRPO
Jun 14, 2022Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote Meeting Adjourned, new meeting set for July 5th at 10am
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote Meeting Adjourned, new meeting set for July 5th at 10am EDT NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced to
Read more →-PRPO
Jun 13, 2022▼ -9.4%on this newsshared move
Page (NASDAQ: PRPO) A Cancer Diagnostics Solutions Company 2022 Corporate Presentation DISCLAIMER This presentation has been prepared by Precipio Inc.(the “Company”) and is general background information ab
David Cohen, Director Board Of Directors 11 Page Established R&D platform to develop practical, efficient diagnostic solutions Two commercially available, revenue generating products Robust R&D pipeline of impactful cancer diagnostic products, each with billion dollar TAMs Revenu
Read more →-PRPO
Mar 23, 2022Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call Conference Call to be held on Monday, April 4 th , 202 2 at 5:00 PM EST NEW HAVEN, CT, Globenewswire - (March 22 nd , 2022) - Specialty cancer d
2021 Fourth Quarter and Year-End Shareholder Update Call Call to be held on Monday, April 4th, 2022 at 5:00 PM EST HAVEN, CT, Globenewswire - (March 22nd, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2021 and year end shar
Read more →-PRPO
Mar 21, 2022Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO NEW HAVEN CT - (
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO HAVEN CT - (March 21, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years
Read more →-PRPO
Feb 24, 2022Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022 NEW HAVEN CT, (
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022 NEW HAVEN CT, (February 24, 2022) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company anticipates
Read more →-PRPO
Nov 2, 2021Precipio Announces Q3-2021 Shareholder Update Call Conference Call to be held on Monday, November 15 th , 2021 at 5:00 PM EST NEW HAVEN, CT, (November 1 st , 2021) - Specialty cancer diagnostics company Precipio, Inc. (N
Q3-2021 Shareholder Update Call Call to be held on Monday, November 15th, 2021 at 5:00 PM EST NEW HAVEN, CT, (November 1st, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2021 update call on Monday, November 15th at 5:00 PM
Read more →-PRPO
Aug 23, 2021Precipio Reschedules Q2-2021 Shareholder Update Call Due to a schedule conflict, the call is moved to Thursday August 26 th at 5:00PM EST NEW HAVEN, CT, (August 20 th , 2021) - Specialty cancer diagnostics company Precip
Precipio Reschedules Q2-2021 Shareholder Update Call a schedule conflict, the call is moved to Thursday August 26th at 5:00PM EST NEW HAVEN, CT, (August 20th, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be rescheduling its Q2-2021 update
Read more →-PRPO
Aug 13, 2021Precipio Announces Q2-2021 Shareholder Update Call Conference Call to be held on Monday, August 23 rd , 2021 at 5:00 PM EST NEW HAVEN, CT, (August 12 th , 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASD
Announces Q2-2021 Shareholder Update Call Call to be held on Monday, August 23rd, 2021 at 5:00 PM EST NEW HAVEN, CT, (August 12th, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23rd at 5:0
Read more →-PRPO
Jul 28, 2021Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M Increase of 65% YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen NEW HAVEN, CT, (
Precipio Announces Preliminary Unaudited Q2-2021 YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen NEW HAVEN, CT, (July 28, 2021) - Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces preliminary unaudited revenues for Q2-2021 demonstr
Read more →-PRPO
May 17, 2021Precipio Announces Q1-2021 and year-end Shareholder Update Call Conference Call to be held on Thursday, May 20 th , 2021 at 5:00 PM EST NEW HAVEN, CT, (May 14 th , 2021) - Specialty cancer diagnostics company Precipio, I
Q1-2021 and year-end Shareholder Update Call Call to be held on Thursday, May 20th, 2021 at 5:00 PM EST 14th, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2021 corporate update call on Thursday, May 20th at 5:00 PM ET. The
Read more →-PRPO
Mar 18, 2021Precipio Announces Q4-2020 and year-end Shareholder Update Call Conference Call to be held on Wednesday, March 31 st , 2021 at 5:00 PM EST NEW HAVEN, CT, (March 18 th , 2021) - Specialty cancer diagnostics company Precip
Q4-2020 and year-end Shareholder Update Call Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST NEW HAVEN, CT, (March 18th, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2020 and year end corporate update call on
Read more →-PRPO
Mar 3, 2021Mr. Richard Sandberg is appointed Chairman of Precipio's Board of Directors NEW HAVEN, CT, (
Sandberg is appointed Chairman of Precipio's Board of Directors CT, (March 3, 2021) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down a
Read more →-PRPO
Nov 12, 2020Precipio Announces Q3-2020 Shareholder Update Call Conference Call to be held on Thursday, November 19 th , 2020 at 5:00 PM EST NEW HAVEN, CT, (November 11 th , 2020) - Specialty cancer diagnostics company Precipio, Inc.
Q3-2020 Shareholder Update Call Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (November 11th, 2020) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2020 corporate update call on Thursday, November
Read more →-PRPO
Sep 7, 2020Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW HAVEN, CT, (September
a Shareholder Call to Discuss its COVID-19 Progress and Future Plans Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW HAVEN, CT, (September 4th, 2020) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),
Read more →-PRPO
Aug 7, 2020Precipio Announces Q2-2020 Corporate Update Call For Shareholders Conference Call to be held on Monday, August 17 th , 2020 at 5:00 PM EST NEW HAVEN, CT, (August 7 th , 2020) - Specialty cancer diagnostics company Precip
Q2-2020 Corporate Update Call For Shareholders Call to be held on Monday, August 17th, 2020 at 5:00 PM EST NEW HAVEN, CT, (August 7th, 2020) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2020 corporate update call on Monday, Augu
Read more →-PRPO
Jul 22, 2020Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1'20 NEW HAVEN, CT, (
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1'20 NEW HAVEN, CT, (July 22, 2020) - Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increas
Read more →-PRPO
May 13, 2020Precipio Announces Q1-2020 Corporate Update Call For Shareholders Conference Call to be held on Tuesday, May 19 th , 2020 at 5:00 PM EST NEW HAVEN, CT, (May 12 th , 2020) - Specialty cancer diagnostics company Precipio,
Announces Q1-2020 Corporate Update Call For Shareholders Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (May 12th, 2020) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Quarter1-2020 corporate update call on
Read more →-PRPO
Mar 16, 2020Precipio Completes the Transaction with Poplar Healthcare's Oncometrix Hematopathology Division Customer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (
Precipio Completes the Transaction with Poplar Healthcare's Oncometrix Hematopathology Division Customer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (March 16, 2020) - Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced to
Read more →-PRPO
Feb 18, 2020PRPO - 8K - 99.1 Poplar Partenrship Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership NEW HAVEN, CT, (
Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership NEW HAVEN, CT, (February 18, 2020) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it is in advanced discussions with Poplar Healthcare to esta
Read more →-PRPO
Jan 13, 2020Precipio announces shareholder update call to kick off 2020 NEW HAVEN, CT, (
Precipio announces shareholder update call to kick off 2020 HAVEN, CT, (January 13, 2020) - Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update call with regard to several strategic in
Read more →-PRPO
Dec 4, 2019PRPO - 8K - 99.1 Press release Dated Dec 4 2019 Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors Douglas Fisher, MD will assume the role of interi
Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors Douglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, CT, (December 4, 2019) Specialty diagnostics company Precipio, Inc. (NA
Read more →-PRPO
Nov 5, 2019Precipio Announces Q3-2019 Corporate Update Call for Shareholders Conference Call to be held on Wednesday, November 13 th , 2019 at 5:30 PM EST NEW HAVEN, CT - (November 4 th , 2019) – Specialty cancer diagnostics
Precipio Announces Q3-2019 Corporate Update Call for Shareholders Conference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW HAVEN, CT - (November 4th, 2019) Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Third Quarte
Read more →-PRPO
Oct 2, 2019Precipio announces shareholder update call on commercial progress Conference call to be held Thursday October 10 th at 5:00PM EST NEW HAVEN, CT, (
Precipio announces shareholder update call on commercial progress Conference call to be held Thursday October NEW HAVEN, CT, (October 2, 2019) - Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will hold a shareholder update call where CEO Ilan Danieli will discu
Read more →-PRPO
Sep 26, 2019PRPO - 8K - 99.1Press release Dated
Clinical Validations for IV-Cell and HemeScreen Completed Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 27, 2019) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that as it approaches the end of Q3
Read more →-PRPO
Aug 13, 2019PRPO-8K - August 13 2019 Press release Letter to Shareholders Precipio Announces Q2-2019 Corporate Update Call for Shareholders Conference Call to be held on Wednesday, August 21 st , 2019 at 5:00 PM EST NEW HAVEN, CT -
Precipio Announces Q2-2019 Corporate Update Call for Shareholders Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW HAVEN, CT - (August 13, 2019) Specialty cancer diagnostics company Precipio, Inc. (NASDAQ PRPO) will be hosting its Second quarter 201
Read more →-PRPO
Jun 17, 2019PRPO - 8K - 991 Press release Letter to Shareholders June 19 2019 Precipio CEO Provides Update Letter To Shareholders NEW HAVEN, CT, (
Precipio CEO Provides Update Letter To Shareholders NEW HAVEN, CT, (June 17, 2019) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. We are all aware of the recent pricing pressure on Precipio's stock. To this end, we would lik
Read more →-PRPO
May 15, 2019PRPO - 8K - 991 Press release Nasdaq compliance Precipio Regains Nasdaq Listing Compliance NEW HAVEN, CT, (May 15 2019) – Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that on
Precipio Regains Nasdaq Listing Compliance NEW HAVEN, CT, (May 15 2019) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing the Company that it had regained compliance with the Bid Price
Read more →-PRPO
Apr 26, 2019Precipio Takes Final Step towards Regaining Nasdaq Compliance Company announces 1-for-15 reverse stock split NEW HAVEN, CT - (
Precipio Takes Final Step towards Regaining Nasdaq Compliance Company announces 1-for-15 reverse stock split NEW HAVEN, CT - (April 26, 2019) Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 reverse stock spli
Read more →-PRPO
Mar 11, 2019PRPO - 8K - Regulation FD 99.1 discl. Letter to Shareholders Precipio CEO Issues Shareholder Update Letter NEW HAVEN, CT, (March 11 th , 2019) – Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), issue
Precipio CEO Issues Shareholder Update Letter NEW HAVEN, CT, (March 11th, 2019) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following letter from CEO Ilan Danieli. Following our recent quarterly conference call, I would like to provide additional inf
Read more →-PRPO
Feb 14, 2019PRPO - 8K - 99.1 for Preliminary results Q4 Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability Shareholder call scheduled for February 21 st at 4:30PM EST
Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), anno
Read more →-PRPO
Nov 19, 2018Precipio Announces Third Quarter 2018 Corporate Update Call for Shareholders Conference Call to Be Held Monday
Precipio Announces Third Quarter 2018 Corporate Update Call for Shareholders Conference Call to Be Held Monday, November 19, 2018 at 5:00 PM ET NEW HAVEN, CT - (November 15, 2018) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its third
Read more →-PRPO
Oct 16, 2018Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017 New Haven, CT, (O
Read more →-PRPO
Sep 27, 2018Precipio Granted 180 Day NASDAQ Extension to Regain Compliance Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, CT, (September 26 th ,
Precipio Granted 180 Day NASDAQ Extension to Regain Compliance Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, CT, (September 26th, 2018) - Specialty cancer diagnostics company Precipio, In
Read more →-PRPO
Aug 23, 2018Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update Conference Call to be held Thursday
Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update Conference Call to be held Thursday August 23, 2018 at 9:00am Eastern Time NEW HAVEN, CT, (August 17, 2018) - Precipio, Inc. (NASDAQ: PRPO), today filed its form 10-Q and released it's fin
Read more →-PRPO
Aug 9, 2018Precipio Appoints New Board Member to Replace Departing Director Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies NEW HAVEN, CT, (
Precipio Appoints New Board Member to Replace Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies NEW HAVEN, CT, (August 9th, 2018) - Specialty cancer diagnostics company Precipio, Inc. (N
Read more →-PRPO
Jul 18, 2018Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18 th , 2018) - Specialty cancer diagnostics compan
Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18th, 2018) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced prelimi
Read more →-PRPO
Jun 15, 2018PRECIPIO INC. ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF SHAREHOLDERS NEW HAVEN, CT, (
PRECIPIO INC. ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF NEW HAVEN, CT, (June 15, 2018) - Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today that the Company's 2018 Annual Meeting of Shareholders, originally scheduled for 9:30 a.m., Eastern Standard Ti
Read more →-PRPO
May 14, 2018Precipio Announce s Preliminary Q 1 2018 Year-over-Year Revenue Increase of 286% Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, CT
Preliminary Q1 2018 Year-over-Year Revenue Increase of 286% Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, CT, (May 14th, 2018) - Specialty diagnostics company Precipio, Inc. (NASDAQ:PRP
Read more →-PRPO
Apr 26, 2018Precipio Announces Participation Details for Upcoming Shareholder Conference Call NEW HAVEN, CT, (
Precipio Announces Participation Details for Upcoming Shareholder Conference Call NEW HAVEN, CT, (April 26, 2018) - Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Mo
Read more →-PRPO
Feb 9, 2018Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter First post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 9 th , 2018) - Specialty diagnostics company Precipio, Inc. (NAS
Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter First post-merger quarter to turn the corner and demonstrate NEW HAVEN, CT, (February 9th, 2018) - Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th
Read more →-PRPO
Nov 21, 2017Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update Conference Call to be held Tuesday
Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update Conference Call to be held Tuesday, November 21, 2017 at 9:00am Eastern Time NEW HAVEN, CT, (November 20, 2017) Precipio, Inc. (NASDAQ: PRPO), today announced financial results for the third q
Read more →-PRPO
Nov 14, 2017Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as Director NEW HAVEN, CT, (
Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as NEW HAVEN, CT, (November 14, 2017) Precipio, Inc. (NASDAQ: PRPO), today announced that on November 8, 2017, Precipio s Board of Directors (the Board ) appointed Samuel D. Ricc
Read more →-PRPO
Nov 13, 2017PRECIPIO, INC. ANNOUNCES CLOSING OF $2,748,000
PRECIPIO, INC. ANNOUNCES CLOSING OF $2,748,000 REGISTERED DIRECT OFFERING NEW HAVEN, CT November 13, 2017 Precipio, Inc. (NASDAQ: PRPO), announced today that it has completed a registered direct offering for the purchase and sale of 2,748 units, each consisting of one share of
Read more →-PRPO
Nov 3, 2017PRECIPIO, INC. ANNOUNCES PRICING OF $2,748,000 REGISTERED DIRECT OFFERING NEW HAVEN, CT, NOVEMBER 3, 2017 PRECIPIO, INC. (NASDAQ: PRPO) , announced it has priced a best efforts registered direct offering for the purchase
PRECIPIO, INC. ANNOUNCES PRICING OF $2,748,000 REGISTERED DIRECT OFFERING NEW HAVEN, CT, NOVEMBER 3, 2017 PRECIPIO, INC. (NASDAQ: PRPO), announced it has priced a best efforts registered direct offering for the purchase and sale of 2,748 units, each consisting of one share of S
Read more →-PRPO
Oct 2, 2017Precipio Elects Jeffrey Cossman, MD, and Douglas Fisher, MD to its Board of Directors NEW HAVEN, Conn., (
Precipio Elects Jeffrey Cossman, MD, and Douglas Fisher, MD to its Board of Directors NEW HAVEN, Conn., (October 2, 2017) Precipio, Inc. (NASDAQ: PRPO), today announced that on September 26, 2017, the Company elected each of Jeffrey Cossman, MD, and Doug Fisher, MD to the Board
Read more →-PRPO
Sep 6, 2017Precipio Provides Shareholder Update Letter NEW HAVEN, Conn., (
Precipio Provides Shareholder Update Letter NEW HAVEN, Conn., (September 06, 2017) Precipio, Inc. (NASDAQ: PRPO), today released the following Letter to its Shareholders: Dear Valued Shareholders, As we enter the second half of 2017, I am delighted to report that we reached t
Read more →-PRPO
Aug 31, 2017PRECIPIO, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING NEW HAVEN, CT, (
PRECIPIO, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING NEW HAVEN, CT, (August 31, 2017) PRECIPIO, INC. (NASDAQ: PRPO), today announced the closing of its previously announced underwritten public offering of 6,000 units, at a public offering price of $1,000 per unit, each comprised
Read more →-PRPO
Aug 23, 2017PRECIPIO, INC. PRICES $6,000,000 PUBLIC OFFERING NEW HAVEN, CT, (
PRECIPIO, INC. PRICES $6,000,000 PUBLIC OFFERING NEW HAVEN, CT, (August 23, 2017) PRECIPIO, INC. (NASDAQ: PRPO), today announced the pricing of an underwritten public offering of units, at a public offering price of $1,000 per unit, each comprised of one share of series B conve
Read more →-PRPO
Aug 1, 2017PRECIPIO ANNOUNCES PROPOSED PUBLIC OFFERING NEW HAVEN, Conn., (
PRECIPIO ANNOUNCES PROPOSED PUBLIC OFFERING NEW HAVEN, Conn., (August 1, 2017) Precipio, Inc. (NASDAQ: PRPO), today announced that it intends to offer for sale its common stock and warrants in an underwritten public offering. The Company intends to use the net proceeds from thi
Read more →-PRPO
Jul 31, 2017PRECIPIO DIAGNOSTICS, LLC INDEX Unaudited Condensed Financial Statements 2 Condensed Balance Sheets at
PRECIPIO DIAGNOSTICS, LLC Unaudited Condensed Financial Statements 2 Condensed Balance Sheets at March 31, 2017 (Unaudited) and December 31, 2016 2 Condensed Statements of Operations for the three months ended March 31, 2017 and 2016 (Unaudited) 3 Condensed Statements o
Read more →-PRPO
Jun 30, 2017PRECIPIO DIAGNOSTICS AND TRANSGENOMIC COMPLETE MERGER Company Renamed Precipio, Inc. To Commence Trading On NASDAQ Under The New Ticker PRPO NEW HAVEN, Conn. & OMAHA, Neb., (
PRECIPIO DIAGNOSTICS AND TRANSGENOMIC Company Renamed Precipio, Inc. To Commence Trading On NASDAQ Under The New Ticker "PRPO" NEW HAVEN, Conn. & OMAHA, Neb., (June 30, 2017) - Precipio Diagnostics, LLC and Transgenomic Inc. (OTCQB: TBIOD) today announced the closing of their
Read more →-PRPO
Jun 6, 2017TRANSGENOMIC STOCKHOLDERS AND PRECIPIO DIAGNOSTICS MEMBERS APPROVE MERGER OMAHA, Neb. and NEW HAVEN, Conn., (
TRANSGENOMIC STOCKHOLDERS AND PRECIPIO DIAGNOSTICS MEMBERS APPROVE MERGER OMAHA, Neb. and NEW HAVEN, Conn., (June 6, 2017) -- Transgenomic, Inc. (OTCBB: TBIO) today announced that its stockholders have approved the merger with Precipio Diagnostics, LLC. Upon completion of the
Read more →-PRPO
May 25, 2017Transgenomic Board Confirms Date and Location of Special Meeting of Stockholders and Announces Reverse Stock Split Ratio OMAHA, Neb. (
Transgenomic Board Confirms Date and Location of Special Meeting of Stockholders and Announces Reverse Stock Split Ratio OMAHA, Neb. (May 25, 2017) -- Transgenomic, Inc. (OTCQB: TBIO), today announced that its Board of Directors confirms its special meeting of stockholders wi
Read more →-PRPO
Apr 17, 2017TRANSGENOMIC CLOSES BRIDGE FINANCING Proceeds Intended to Facilitate Completion of Merger with Precipio Diagnostics During Second Quarter of 2017 OMAHA, Neb. (
TRANSGENOMIC CLOSES BRIDGE FINANCING Proceeds Intended to Facilitate Completion of Merger with Precipio Diagnostics During Second Quarter of 2017 OMAHA, Neb. (April 17, 2017) - Transgenomic, Inc. (OTCQB:TBIO) today reported that it has received $1.15 million in proceeds from
Read more →-PRPO
Feb 21, 2017TRANSGENOMIC PROVIDES UPDATE ON ITS PLANNED MERGER AND REPORTS CHANGE IN LISTING STATUS OMAHA, Neb. (
TRANSGENOMIC PROVIDES UPDATE ON ITS PLANNED MERGER AND REPORTS CHANGE IN LISTING STATUS OMAHA, Neb. (February 21, 2017) -- Transgenomic, Inc. (TBIO) (OTQB: TBIO) today reported that trading in its shares will begin on the OTCQB exchange under the ticker "TBIO" effective at th
Read more →-PRPO
Oct 13, 2016VOTING AGREEMENT THIS VOTING AGREEMENT (this " Agreement "), dated as of October , 2016, is made by and among Transgenomic, Inc., a Delaware corporation (" Parent "), Precipio Diagnostics, LLC, a Delaware limited liabili
THIS VOTING AGREEMENT (this "Agreement"), dated as of October , 2016, is made by and among Transgenomic, Inc., a Delaware corporation ("Parent"), Precipio Diagnostics, LLC, a Delaware limited liability company (the "Company"), and the undersigned holder ("Stockholder") of shar
Read more →-PRPO
Aug 12, 2016Transgenomic Reports Second Quarter 2016 Financial Results Conference Call to be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Second Quarter 2016 Conference Call to be Held at 5:00 PM Omaha, Neb. (August 12, 2016) - Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) today reported financial results for the second quarter ended June 30, 2016, and provided a business Second Quarter Financi
Read more →-PRPO
Jan 11, 2016TRANSGENOMIC ANNOUNCES PRIVATE PLACEMENT FINANCING OMAHA, Neb. (
TRANSGENOMIC ANNOUNCES PRIVATE PLACEMENT OMAHA, Neb. (January 11, 2016) -- Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it raised gross
Read more →-PRPO
Jan 11, 2016TRANSGENOMIC ANNOUNCES CONVERSION OF SERIES A AND B PREFERRED SECURITIES AND EXTENSION OF LOAN MATURITY DATE Simplified Capital Structure Provides Financial Flexibility for Broad C ommercialization of ICE-COLD PCR in 201
TRANSGENOMIC ANNOUNCES CONVERSION OF SERIES A AND B PREFERRED SECURITIES AND EXTENSION OF LOAN MATURITY DATE Capital Structure Provides Financial Flexibility for Broad Commercialization of ICE-COLD PCR in 2016 OMAHA, Neb. (January 11, 2016) -- Transgenomic, Inc. (NASDAQ: TBI
Read more →-PRPO
Dec 1, 2015TRANSGENOMIC FINALIZES DIVESTMENT OF ITS GENETIC ASSAYS & PLATFORMS BUSINESS UNIT Divestiture to ADSTEC Allows Transgenomic to Focus on Accelerating Commercialization of Its High Potential Multiplexed ICE COLD-PCR (MX-IC
FINALIZES DIVESTMENT OF ITS GENETIC ASSAYS & PLATFORMS Divestiture to ADSTEC Allows Transgenomic to Focus on Accelerating Commercialization of Its High Potential Multiplexed ICE COLD-PCR OMAHA, Neb. (December 1, 2015) -- Transgenomic, Inc. (NASDAQ: TBIO) today announced that
Read more →-PRPO
Nov 12, 2015Transgenomic Reports Third Quarter 2015 Financial Results Conference Call to be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Third Quarter 2015 Conference Call to be Held at 5:00 PM Omaha, Neb. (November 12, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the third quarter ended September 30, 2015, and provided a business update. During the third
Read more →-PRPO
Sep 30, 2015TRANSGENOMIC SIGNS BINDING TERM SHEET TO DIVEST GENETIC ASSAYS & PLATFORMS BUSINESS UNIT Transgenomic's Third Divestiture is Expected to Enable the Company to Fully Focus Its Business Strategy on Accelerating Commerciali
SIGNS BINDING TERM SHEET TO DIVEST GENETIC ASSAYS & PLATFORMS BUSINESS UNIT Third Divestiture is Expected to Enable the Company to Fully Focus Its Business Strategy on Accelerating Commercialization of Its Multiplexed ICE COLD-PCR (MX-ICP) Technology Neb. (September 30, 2015)
Read more →-PRPO
Sep 9, 2015TRANSGENOMIC SELLS ION CHROMATOGRAPHY PRODUCT LINE AND ASSETS TO EDGE BIOSYSTEMS, INC. -$2.1 Million Sale Continues Transgenomic's Strategy of Selectively Monetizing Legacy Assets and Generating Non-Dilutive Cash to Allo
TRANSGENOMIC SELLS ION CHROMATOGRAPHY PRODUCT LINE AND ASSETS TO EDGE -$2.1 Million Sale Continues Transgenomic's Strategy of Selectively Monetizing Legacy Assets and Generating Non-Dilutive Cash to Allow Focus on Products for High Growth Molecular Diagnostics and Personali
Read more →-PRPO
Aug 13, 2015Transgenomic Reports Second Quarter 2015 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Second Quarter 2015 Conference Call to Be Held at 5:00 PM Omaha, Neb. (August 13, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the second quarter ended June 30, 2015, and provided Second Quarter Financial Results Net sal
Read more →-PRPO
Jun 22, 2015TRANSGENOMIC ANNOUNCES PLANS TO LAUNCH LIQUID BIOPSY CANCER TEST PIPELINE DURING 2015 Plans to Release Up to Six New Lab-Based Cancer Tests This Year Targeting Actionable Mutations in Melanoma, Lung Cancer and Colorectal
TRANSGENOMIC ANNOUNCES PLANS TO LAUNCH LIQUID BIOPSY CANCER TEST PIPELINE DURING 2015 Plans to Release Up to Six New Lab-Based Cancer Tests This Year Targeting Actionable Mutations in Melanoma, Lung Cancer and Colorectal Cancer for Use with Tissue or Liquid OMAHA, Neb. (June
Read more →-PRPO
Jun 9, 2015Transgenomic Expands Board of Directors and Executive Team New Director Mya Thomae is Regulatory Head at Illumina and Marketing Vice President Harjit Kullar Brings Sales & Marketing Expertise from Life Technologies, Ther
Transgenomic Expands Board of Directors New Director Mya Thomae is Regulatory Head at Illumina and Marketing Vice President Harjit Kullar Brings Sales & Marketing Expertise from Life Technologies, Thermo OMAHA, Neb. (June 9, 2015) -- Transgenomic, Inc. (NASDAQ: TBIO), a devel
Read more →-PRPO
May 14, 2015Transgenomic Reports First Quarter 2015 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports First Quarter 2015 Conference Call to Be Held at 5:00 PM Omaha, Neb. (May 14, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the first quarter ended March 31, 2015, and provided a business update. First Quarter Financial Re
Read more →-PRPO
Apr 15, 2015TRANSGENOMIC PROVIDES FINANCIAL AND BUSINESS UPDATE Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
PROVIDES FINANCIAL AND BUSINESS UPDATE Conference Call to Be Held at 5:00 PM Omaha, Neb. (April 15, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today provided a business update and financial review for the year ended December 31, 2014. "In 2014, we made good progress in buildin
Read more →-PRPO
Feb 26, 2015Transgenomic Announces Commencement of Public Offering of Common Stock Omaha, Neb. (
Transgenomic Announces Commencement of Public Offering of Common Stock Omaha, Neb. (February 26, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today announced that it intends to offer shares of the company's common stock and corresponding warrants to purchase shares of the compan
Read more →-PRPO
Jan 14, 2015Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing OneMed Conference San Francisco, CA Paul Kinnon, President & CEO January 2015
1 Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing OneMed Conference San Francisco, CA Paul Kinnon, President & CEO January 2015 2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking
Read more →-PRPO
Dec 11, 2014Strategic Update Advancing outcomes in oncology with groundbreaking molecular testing technology Company Update Paul Kinnon, President & CEO December 11 th 2014 2 Forward - Looking Statements Certain statements in this p
1 Strategic Update Advancing outcomes in oncology with groundbreaking molecular testing technology Company Update Paul Kinnon, President & CEO December 11 th 2014 2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" of
Read more →-PRPO
Nov 5, 2014TRANSGENOMIC announces executive changes OMAHA, Neb. (
announces executive changes OMAHA, Neb. (November 5, 2014) -- Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services,
Read more →-PRPO
Oct 30, 2014Transgenomic Reports Third Quarter 2014 Financial Results Conference Call to Be Held at 8:30 AM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Third Quarter 2014 Financial Results Conference Call to Be Held at 8:30 AM Omaha, Neb. (October 30, 2014) - Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the third quarter ended September 30, 2014, and provided a business update.
Read more →-PRPO
Oct 22, 2014Transgenomic Announces $2.375 Million Private Placement Financing OMAHA, Neb. (
Transgenomic Announces $2.375 Million Private Placement Financing OMAHA, Neb. (October 22, 2014) - Transgenomic, Inc. (NASDAQ: TBIO) announced today that it has raised gross proceeds of approximately $2.375 million in a private placement financing with a syndicate of new and
Read more →-PRPO
Aug 6, 2014Transgenomic Reports Second Quarter 2014 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today OMAHA, Neb.--(BUSINESS WIRE)
Reports Second Quarter 2014 Financial Results Call to Be Held at 5:00 PM Eastern Time Today OMAHA, Neb.--(BUSINESS WIRE)--August 6, 2014--Transgenomic, Inc. (NASDAQ:TBIO) today reported financial results for the second quarter ended June 30, 2014, and provided a business upda
Read more →-PRPO
Jul 2, 2014TRANSGENOMIC SELLS RIGHTS TO SURVEYOR MUTATION DETECTION TECHNOLOGY AND ASSETS TO INTEGRATED DNA TECHNOLOGIES, INC. Selective Monetization of Research Market Assets Reflects Strategic Focus on Higher Growth olecular Diag
TRANSGENOMIC SELLS RIGHTS TO SURVEYOR MUTATION DETECTION TECHNOLOGY AND ASSETS TO INTEGRATED DNA TECHNOLOGIES, INC. Selective Monetization of Research Market Assets Reflects Strategic Focus on Higher Growth olecular Diagnostics and Personalized Medicine Sectors OMAHA, Neb.
Read more →-PRPO
May 15, 2014JOHN D. THOMPSON JOINS TRANSGENOMIC'S BOARD OF DIRECTORS OMAHA, Neb. (
D. THOMPSON JOINS TRANSGENOMIC'S BOARD OF DIRECTORS OMAHA, Neb. (May 15, 2014) -- Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical an
Read more →-PRPO
May 7, 2014Transgenomic Reports First Quarter 2014 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Reports First Quarter 2014 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (May 7, 2014) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the first quarter ended March 31, 2014, and provided a business update. Fi
Read more →-PRPO
May 6, 2014Transgenomic Announces Uplisting to the NASDAQ Capital Market OMAHA, Neb. (
Announces Uplisting to the NASDAQ Capital Market OMAHA, Neb. (May 6, 2014) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and res
Read more →-PRPO
Mar 19, 2014Dr. Michael A. Luther Joins Transgenomic's Board of Directors OMAHA, Neb. (
Dr. Michael A. Luther Joins Transgenomic's OMAHA, Neb. (March 19, 2014) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research
Read more →-PRPO
Mar 12, 2014Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results Conference Call to Be Held at 5:00 PM Omaha, Neb. (March 12, 2014) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2013, and prov
Read more →-PRPO
Mar 6, 2014Transgenomic Announces $7 Million Convertible Preferred Stock Financing OMAHA, Neb. (
Transgenomic Announces $7 Million Convertible Preferred Stock Financing 6, 2014) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and
Read more →-PRPO
Jan 16, 2014Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio Proposed Uplisting Expected to Benefit the Company Through Greater Visibility, Access to Capital, and Incr
Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio Proposed Uplisting Expected to Benefit the Company Through Greater Visibility, Access to Capital, and Increased Share Liquidity OMAHA, Neb. (Jan 16, 2014) -- Tra
Read more →-PRPO
Nov 6, 2013Transgenomic Reports Third Quarter 2013 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Third Quarter 2013 Conference Call to Be Held at 5:00 PM Omaha, Neb. (November 6, 2013) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and nine months ended September 30, 2013, and provided a business update. Third Qua
Read more →-PRPO
Oct 15, 2013PDI MEDIA AND INVESTOR CONTACT: Melody Carey Rx Communications Group, LLC (917) 322-2571 mcarey@rxir.com TRANSGENOMIC MEDIA AND INVESTOR CONTACT: Susan Kim Argot Partners (212) 600-1902 susan@argotpartners.com PDI, Inc.
PDI MEDIA AND INVESTOR CONTACT: Rx Communications Group, LLC TRANSGENOMIC MEDIA AND INVESTOR CONTACT: susan@argotpartners.com PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test - Companies enter long-term collaboration
Read more →-PRPO
Sep 30, 2013Transgenomic Announces Executive Changes Paul Kinnon Named President, Chief Executive Officer and Director OMAHA, Neb. (
Transgenomic Announces Executive Changes Paul Kinnon Named President, Chief Executive Officer and Director OMAHA, Neb. (Sept 30, 2013) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited d
Read more →-PRPO
Aug 6, 2013Transgenomic Reports Second Quarter 2013 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Today Omaha, Neb. (
Transgenomic Reports Second Quarter 2013 Conference Call to Be Held at 5:00 PM Omaha, Neb. (August 6, 2013) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and six months ended, June 30, 2013, and provided a business update. Second Quarter
Read more →-PRPO
May 8, 2013Transgenomic Reports First Quarter 2013 Financial Results Conference Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (
Transgenomic Reports First Quarter 2013 Conference Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (May 8, 2013) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the first quarter ended March 31, 2013 and provided a business update. First Qu
Read more →-PRPO
Mar 13, 2013Transgenomic Reports Fourth Quarter and Fiscal Year 2012 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Omaha, Neb. (
Transgenomic Reports Fourth Quarter and Fiscal Year 2012 Financial Results Conference Call to Be Held at 5:00 PM Omaha, Neb. (March 13, 2013) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2012 and provi
Read more →-PRPO
Mar 13, 2013Transgenomic Secures $8.0 Million Credit Facility Omaha, Neb. (
Transgenomic Secures $8.0 Million Credit Omaha, Neb. (March 13, 2013) - Transgenomic, Inc. (OTC/BB: TBIO) today announced that it has secured an $8.0 million term and revolving credit facility from Third Security Senior Staff 2008 LLC, Third Security Staff 2010 LLC, and Third
Read more →-PRPO
Jan 25, 2013Transgenomic Announces $8.3 Million Private Placement Financing OMAHA, Neb. (
Transgenomic Announces $8.3 Million Private Placement Financing (January 25, 2012) Transgenomic, Inc. (OTCBB: TBIO) announced today that it has entered into definitive agreements with a syndicate of institutional and other accredited investors to raise gross proceeds of $8.3 mil
Read more →-PRPO
Nov 7, 2012Transgenomic Reports Third Quarter 2012 Financial Results Conference Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (
Transgenomic Reports Third Quarter 2012 Conference Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (November 7, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and nine months ended, September 30, 2012, and provided Third Qu
Read more →-PRPO
Sep 13, 2012Transgenomic Announces Appointment of Mark P. Colonnese as Chief Financial Officer Omaha, Neb. (
Transgenomic Announces Appointment of Mark P. Colonnese as Chief Financial Officer Omaha, Neb. (September 13, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today announced the appointment of Mark P. Colonnese as Executive Vice President and Chief Financial Officer of the Company
Read more →-PRPO
Aug 28, 2012Transgenomic Acquires ScoliScore Adolescent Idiopathic Scoliosis Prognostic Test from Axial Biotech Commercially Established, Highly Accurate Test Reduces Dangerous Radiation Exposure in Adolescents Diagnosed with Scolio
Transgenomic Acquires ScoliScore Adolescent Idiopathic Scoliosis Prognostic Test from Axial Biotech Commercially Established, Highly Accurate Test Reduces Dangerous Radiation Exposure in Adolescents Diagnosed with Scoliosis OMAHA, Neb. (August 28, 2012) - Transgenomic, Inc.
Read more →-PRPO
Aug 1, 2012Transgenomic Reports Second Quarter 2012 Financial Results Conference Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (
Reports Second Quarter 2012 Financial Results Call to Be Held Today at 5:00 PM Eastern Time Omaha, Neb. (August 1, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and six months ended, June 30, 2012, and provided a business second quar
Read more →-PRPO
May 8, 2012Transgenomic Reports First Quarter 2012 Financial Results Conference Call to Be Held at 5:00 PM Eastern Time Omaha, Neb. (
Transgenomic Reports First Quarter 2012 Conference Call to Be Held at 5:00 PM Omaha, Neb. (May 8, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months ended, March 31, 2012, and provided a business update. progress in the first quart
Read more →-PRPO
Mar 7, 2012Transgenomic Reports Fiscal Year 2011 Financial Results Annual Revenues Increase 59% Year-over-Year; Company Records Net Profit for Fourth Quarter; Conference Call to Be Held at 11:30 AM Eastern Time Omaha, Neb. (
Transgenomic Reports Fiscal Year 2011 Annual Revenues Increase 59% Year-over-Year; Company Records Net Profit for Fourth Conference Call to Be Held at 11:30 AM Eastern Time Omaha, Neb. (March 7, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for t
Read more →-PRPO
Feb 3, 2012Transgenomic Announces $22.0 Million Private Placement Financing OMAHA, Neb. (
Transgenomic Announces $22.0 Million Private Placement Financing OMAHA, Neb. (February 3, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today announced that it has entered into definitive agreements with institutional and other accredited investors to raise approximately $22.0 mi
Read more →-PRPO
Jan 6, 2012Transgenomic Announces $3 Million Convertible Note Financing OMAHA, Neb. (
Transgenomic Announces $3 Million Convertible Note Financing OMAHA, Neb. (January 6, 2012) - Transgenomic, Inc. (OTC/BB: TBIO) today announced that it has entered into a Convertible Promissory Note Purchase Agreement (the "Purchase Agreement") in the aggregate amount of $3.0 mil
Read more →-PRPO
Nov 9, 2011Unassociated Document Transgenomic Reports Third Quarter Financial Results Quarterly Revenues Increase 87% Year-over-Year Conference Call to Be Held at 5:00 PM Eastern Time Omaha, Neb. (
Transgenomic Reports Third Quarter Financial Results Quarterly Revenues Increase 87% Year-over-Year Conference Call to Be Held at 5:00 PM Eastern Time Omaha, Neb. (November 9, 2011) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and nine mon
Read more →-PRPO
Oct 6, 2011Transgenomic, Inc. Craig - Hallum 2nd Annual Alpha Select Conference
Transgenomic, Inc. Craig - Hallum 2nd Annual Alpha Select Conference October 6, 2011 Offering innovative products and services for personalized medicine (OTCBB: TBIO) 1 2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statement
Read more →-PRPO
Sep 16, 2011INVESTOR PRESENTATION SLIDES Transgenomic, Inc. Rodman & Renshaw 13th Annual Healthcare Conference September 2011 Offering innovative products and services for personalized medicine (OTCBB: TBIO) 1 2 Forward - Looking St
Transgenomic, Inc. Rodman & Renshaw 13th Annual Healthcare Conference September 2011 Offering innovative products and services for personalized medicine (OTCBB: TBIO) 1 2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statement
Read more →-PRPO
May 12, 2011Transgenomic Reports First Quarter Financial Results Net Sales of $7.5 million, up 37 percent Conference call begins at 5:00 p.m. Eastern Time today
Transgenomic Reports First Quarter Financial Results Net Sales of $7.5 million, up 37 percent Conference call begins at 5:00 p.m. Eastern Time today OMAHA, Neb., May 12, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months
Read more →-PRPO
Mar 10, 2011Transgenomic Reports Fourth Quarter Financial Results Conference call begins at 11:00 a.m. Eastern Time tomorrow
Transgenomic Reports Fourth Quarter Financial Results Conference call begins at 11:00 a.m. Eastern Time tomorrow OMAHA, Neb., March 10, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today reported financial results for the three and 12 months ended December
Read more →-PRPO
Dec 29, 2010Transgenomic Announces Closing of the Acquisition of Clinical Data's Diagnostic Business and the Closing of a $6 Million Financing OMAHA, Nebraska (
Announces Closing of the Acquisition of Clinical Data's Diagnostic Business and the Closing of a $6 Million Financing OMAHA, Nebraska (December 29, 2010) - Transgenomic, Inc. (OTCBB: TBIO) announced today that it has closed the acquisition of Clinical Data, Inc.'s (NasdaqGM:
Read more →-PRPO
Nov 30, 2010Transgenomic, Inc. To Purchase Clinical Data, Inc. s Diagnostic Business --Addition of high-growth business accelerates expansion into molecular diagnostics -Conference call to be held on
Transgenomic, Inc. To Purchase Clinical Data, Inc.'s Diagnostic Business --Addition of high-growth business accelerates expansion into molecular diagnostics -Conference call to be held on December 6, 2010- OMAHA, Neb., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
Read more →-PRPO
Aug 12, 2010Transgenomic Reports Second Quarter Financial Results Conference call begins at 5:00 p.m. Eastern Time today OMAHA, Neb., Aug. 12 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today reported fin
Transgenomic Reports Second Quarter Financial Results Conference call begins at 5:00 p.m. Eastern Time today OMAHA, Neb., Aug. 12 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today reported financial results for the three and six months ended June 30,
Read more →-PRPO
May 5, 2010Unassociated Document Transgenomic Reports First Quarter Financial Results Conference call begins at 5:00 p.m. Eastern Time today OMAHA , Neb. (May 5 , 2010 ) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial
Transgenomic Reports First Quarter Financial Results call begins at 5:00 p.m. Eastern Time today OMAHA, Neb. (May 5, 2010) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months ended March 31, 2010, and provided a business update. First Q
Read more →-PRPO
Feb 24, 2010Unassociated Document Transgenomic Reports Fourth Quarter Financial Results Conference call begins at 5:00 p.m. Eastern Time today OMAHA , Neb. (
Transgenomic Reports Fourth Quarter Financial Results call begins at 5:00 p.m. Eastern Time today OMAHA, Neb. (February 24, 2010) - Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three and 12 months ended December 31, 2009, and provided a business
Read more →-PRPO
Nov 5, 2009Thursday
Inc. Reports Third Quarter 2009 Results Neb., November 5, 2009 - Transgenomic, Inc. (OTCBB: TBIO.OB) today announced financial results for the quarter ended September 30, 2009. The Company's financial results are presented in the tables Company reported a net loss of $366,000
Read more →-PRPO
Aug 12, 2009Wednesday
Inc. Reports Second Quarter 2009 Results Neb., August 12, 2009 - Transgenomic, Inc. (OTCBB: today announced financial results for the quarter ended June 30, 2009. The Company's financial results are presented in the tables that Company reported a net loss of $730,000 or $0.01
Read more →-PRPO
May 22, 2009Unassociated Document Friday
Inc. Announces Appointment of New Board Members Neb., May 22, 2009 - Transgenomic, Inc. (OTC BB: announces that it has appointed Antonius P. Schuh, Ph.D. and Michael B. McNulty to its Board of Directors. is the Founding Chairman and Chief Executive Officer of Sorrento Therape
Read more →-PRPO
Mar 18, 2009Unassociated Document Wednesday
Inc. Reports Fourth Quarter and Fiscal Year 2008 Results Neb., March 18, 2009 - Transgenomic, Inc. (OTCBB: TBIO.OB) today announced financial results for the fourth quarter and year ended December 31, 2008. The Company's financial results are presented in the tables that foll
Read more →-PRPO
May 7, 2008v113094_ex99.txt Wednesday
Wednesday, May 7, 2008 COMPANY PRESS RELEASE Transgenomic, Inc. Reports First Quarter 2008 Results OMAHA, Neb., May 7, 2008 - Transgenomic, Inc. (OTCBB: TBIO.OB) today announced financial results for the quarter ended March 31, 2008. The Company's financial results are prese
Read more →-PRPO
Feb 28, 2008v105339_ex99-1.txt TO BUSINESS AND MEDICAL EDITORS: Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results OMAHA, Neb., Feb. 28 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) toda
TO BUSINESS AND MEDICAL EDITORS: Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results OMAHA, Neb., Feb. 28 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced financial results for the fourth quarter and year ended Decembe
Read more →-PRPO
Feb 5, 2008v102065_ex99-1.txt Transgenomic Appoints David Pauluzzi to Board of Directors Former Quest Executive Director Brings Extensive Strategic Marketing Expertise
Transgenomic Appoints David Pauluzzi to Board of Directors Former Quest Executive Director Brings Extensive Strategic Marketing Expertise OMAHA, Neb., February 5, 2008 - Transgenomic, Inc. (OTCBB: TBIO.OB), today announced that it has appointed David P. Pauluzzi to its Board o
Read more →Competitive Position
How PRPO ranks across every disease it competes inCompetitive Position is a premium feature
See how PRPO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial